CN101213204B - 丙型肝炎病毒核酸疫苗 - Google Patents
丙型肝炎病毒核酸疫苗 Download PDFInfo
- Publication number
- CN101213204B CN101213204B CN2006800216989A CN200680021698A CN101213204B CN 101213204 B CN101213204 B CN 101213204B CN 2006800216989 A CN2006800216989 A CN 2006800216989A CN 200680021698 A CN200680021698 A CN 200680021698A CN 101213204 B CN101213204 B CN 101213204B
- Authority
- CN
- China
- Prior art keywords
- hcv
- sequence
- carrier
- seq
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
CDS | 产物 | CDS边界(NCBI形式) | 链 |
CDS1 | E1A25.5K | 589..991,1243..1544 | 正向的 |
CDS2 | E1A30.8K | 589..1129,1243..1544 | 正向的 |
CDS3 | E1B22K | 1716..2279 | 正向的 |
CDS4 | E1B57K | 2021..3544 | 正向的 |
CDS5 | IX | 3640..4104 | 正向的 |
CDS6 | IVa2 | 4163..5499,5778..5790 | 互补的 |
CDS7 | Pol | 5269..8865,14228..14236 | 互补的 |
CDS8 | pTP | 8664..10667,14228..14236 | 互补的 |
CDS9 | 48K产物 | 11120..12379 | 正向的 |
CDS10 | pIIIa | 12403..14181 | 正向的 |
CDS11 | III | 14273..16054 | 正向的 |
CDS12 | pVII | 16069..16665 | 正向的 |
CDS13 | V | 16738..17853 | 正向的 |
CDS14 | pX | 17878..18123 | 正向的 |
CDS15 | pVI | 18219..18974 | 正向的 |
CDS16 | 外显子 | 19086..21968 | 正向的 |
CDS | 产物 | CDS边界(NCBI形式) | 链 |
CDS17 | 蛋白酶 | 21998..22627 | 正向的 |
CDS18 | DBP | 22743..24395 | 互补的 |
CDS19 | 92K产物 | 24445..26940 | 正向的 |
CDS20 | 22K产物 | 26630..27229 | 正向的 |
CDS21 | 33K产物 | 26630..26966,27169..27551 | 正向的 |
CDS22 | pVIII | 27626..28309 | 正向的 |
CDS23 | E312K | 28310..28627 | 正向的 |
CDS24 | E3CR1-α0 | 29125..29325 | 正向的 |
CDS25 | E3gp18K | 29328..29819 | 正向的 |
CDS26 | E333K | 29848..30738 | 正向的 |
CDS27 | E3A11K | 31293..31589 | 正向的 |
CDS28 | E3RIDα | 31601..31873 | 正向的 |
CDS29 | E3RIDβ | 31876..32274 | 正向的 |
CDS30 | E315K | 32267..32653 | 正向的 |
CDS31 | U外显子 | 32684..32848 | 互补的 |
CDS32 | 尾丝 | 32859..34490 | 正向的 |
CDS33 | E4ORF6/7 | 34698..34973,35685..35858 | 互补的 |
CDS34 | E4ORF6 | 34974..35858 | 互补的 |
CDS35 | E4ORF4 | 35758..36123 | 互补的 |
CDS36 | E4ORF3 | 36139..36486 | 互补的 |
CDS37 | E4ORF2 | 36483..36875 | 互补的 |
CDS38 | E4ORF1 | 36928..37314 | 互补的 |
CDS | 产物 | CDS边界(GenBank形式) | 链 |
CDS1 | E1A24.6K | 576..1050,1229..1437 | 正向的 |
CDS2 | E1A28.3K | 576..1143,1229..1437 | 正向的 |
CDS3 | E1B22.6K | 1601..2179 | 正向的 |
CDS4 | E1B9.9K | 1906..2186,3322..3340 | 正向的 |
CDS5 | E1B18.4K | 1906..2216,3204..3420 | 正向的 |
CDS6 | E1B55.7K | 1906..3420 | 正向的 |
CDS7 | IX | 3505..3933 | 正向的 |
CDS8 | IVa2 | 3993..5326,5605..5617 | 互补的 |
CDS9 | Pol | 5096..8455 | 互补的 |
CDS10 | 21.1K产物 | 7877..8461 | 正向的 |
CDS11 | pTP72.5K | 8458..10347 | 互补的 |
CDS12 | 44.3K产物 | 10845..12020 | 正向的 |
CDS13 | 65.5K产物 | 12044..13810 | 正向的 |
CDS14 | pIII | 13889..15511 | 正向的 |
CDS15 | pVII | 15515..16099 | 正向的 |
CDS16 | pV | 16144..17181 | 正向的 |
CDS17 | 8.5K产物 | 17204..17437 | 正向的 |
CDS18 | pVI | 17509..18237 | 正向的 |
CDS19 | 外显子 | 18329..21154 | 正向的 |
CDS20 | 23.6K产物 | 21179..21802 | 正向的 |
CDS21 | E2A | 21882..23417 | 互补的 |
CDS22 | 88.5K产物 | 23443..25842 | 正向的 |
CDS23 | 24.9K产物 | 25556..25886,26056..26399 | 正向的 |
CDS24 | pVIII | 26471..27154 | 正向的 |
CDS25 | E312.1K | 27155..27475 | 正向的 |
CDS26 | E323K | 27429..27503,27692..28055 | 正向的 |
CDS27 | E319.6K | 28037..28570 | 正向的 |
CDS | 产物 | CDS边界(GenBank形式) | 链 |
CDS28 | E322.3K | 29332..29946 | 正向的 |
CDS29 | E332.5K | 29961..30857 | 正向的 |
CDS30 | E326.7K | 28600..29319 | 正向的 |
CDS31 | E310.5K | 30865..31140 | 正向的 |
CDS32 | E316.4K | 31146..31577 | 正向的 |
CDS33 | E315.2K | 31570..31977 | 正向的 |
CDS34 | Fiber | 32254..33531 | 正向的 |
CDS35 | E415.7K | 33638..33889,34621..34791 | 互补的 |
CDS36 | E434.9K | 33886..34791 | 互补的 |
CDS37 | E413.9K | 34697..35062 | 互补的 |
CDS38 | E413.6K | 35072..35425 | 互补的 |
CDS39 | E414.6K | 35422..35811 | 互补的 |
CDS40 | E413.8K | 35851..36225 | 互补的 |
Claims (9)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69152305P | 2005-06-17 | 2005-06-17 | |
US60/691,523 | 2005-06-17 | ||
US69951405P | 2005-07-15 | 2005-07-15 | |
US60/699,514 | 2005-07-15 | ||
PCT/EP2006/005697 WO2006133911A2 (en) | 2005-06-17 | 2006-06-13 | Hepatitis c virus nucleic acid vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101213204A CN101213204A (zh) | 2008-07-02 |
CN101213204B true CN101213204B (zh) | 2013-06-19 |
Family
ID=37074602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800216989A Active CN101213204B (zh) | 2005-06-17 | 2006-06-13 | 丙型肝炎病毒核酸疫苗 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9056090B2 (zh) |
EP (2) | EP2570423B1 (zh) |
JP (1) | JP5475279B2 (zh) |
CN (1) | CN101213204B (zh) |
AU (1) | AU2006257323B2 (zh) |
CA (1) | CA2610919C (zh) |
ES (1) | ES2948791T3 (zh) |
HK (1) | HK1123055A1 (zh) |
WO (1) | WO2006133911A2 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5475279B2 (ja) | 2005-06-17 | 2014-04-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | C型肝炎ウイルス核酸ワクチン |
US20100310605A1 (en) * | 2007-12-18 | 2010-12-09 | Peking University People's Hospital | anti-hcv vaccine and preparation methods and uses thereof |
EP2250255A2 (en) | 2008-03-04 | 2010-11-17 | The Trustees of the University of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
AU2008363596B2 (en) * | 2008-10-29 | 2015-04-30 | Inovio Pharmaceuticals, Inc | Improved HCV vaccines and methods for using the same |
BRPI1008018A2 (pt) | 2009-02-02 | 2016-03-15 | Okairos Ag | ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos |
US9526777B2 (en) | 2010-04-16 | 2016-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein |
KR101913674B1 (ko) * | 2011-10-24 | 2018-10-31 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 hcv 백신 및 이것을 사용하는 방법 |
SG11201407343XA (en) | 2012-05-18 | 2014-12-30 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
JP6983665B2 (ja) * | 2015-06-12 | 2021-12-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
JP2023551743A (ja) * | 2021-01-21 | 2023-12-12 | 株式会社 セリッド | 複製能のあるアデノウイルスを包含しない新規アデノウイルスベクター、およびこれの使用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428792B1 (en) * | 1996-05-24 | 2002-08-06 | Chiron Corporation | Hepatitis C virus multiple copy epitope fusion antigens |
WO2003031588A2 (en) * | 2001-10-11 | 2003-04-17 | Merck & Co., Inc. | Hepatitis c virus vaccine |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5266313A (en) | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5863542A (en) | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
IT1270939B (it) * | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
US5989245A (en) | 1994-03-21 | 1999-11-23 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
ATE278794T1 (de) * | 1995-06-15 | 2004-10-15 | Crucell Holland Bv | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
JP3945822B2 (ja) * | 1996-05-24 | 2007-07-18 | カイロン コーポレイション | 複数エピトープ融合タンパク質 |
CA2257137A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
FR2761689B1 (fr) * | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
IL132103A0 (en) | 1997-04-03 | 2001-03-19 | Eletrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
WO1999030132A1 (fr) | 1997-12-09 | 1999-06-17 | Matsushita Electric Industrial Co., Ltd. | Procede de production d'une electrode destinee a des cellules secondaires electrolytiques non aqueuses |
JP2002511396A (ja) | 1998-04-14 | 2002-04-16 | メルク エンド カムパニー インコーポレーテッド | ポリヌクレオチド製剤の無針投与 |
GB9810756D0 (en) | 1998-05-19 | 1998-07-15 | Angeletti P Ist Richerche Bio | Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
US6156588A (en) | 1998-06-23 | 2000-12-05 | Vlsi Technology, Inc. | Method of forming anti-fuse structure |
EP1232267B1 (en) | 1999-10-27 | 2013-03-20 | Novartis Vaccines and Diagnostics, Inc. | Activation of hcv-specific t cells |
CN101684146A (zh) | 1999-11-24 | 2010-03-31 | 诺华疫苗和诊断公司 | 新颖的hcv非结构多肽 |
JP4399255B2 (ja) | 2001-06-22 | 2010-01-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 細菌の形質転換体を迅速に選別する方法および新規なサルアデノウイルス蛋白質 |
CA2495546A1 (en) | 2002-08-22 | 2004-03-04 | Merck & Co., Inc. | Methods for propagating adenovirus and virus produced thereby |
CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
TWI291500B (en) | 2003-05-07 | 2007-12-21 | Univ Southern California | Method of electrochemically fabricating multilayer structures having improved interlayer adhesion |
PL1711518T3 (pl) | 2004-01-23 | 2010-06-30 | St Di Richerche Di Biologia Molecolare P Angeletti S P A | Nośniki szczepionek pochodzące od szympansich adenowirusów |
JP5475279B2 (ja) | 2005-06-17 | 2014-04-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | C型肝炎ウイルス核酸ワクチン |
-
2006
- 2006-06-13 JP JP2008516223A patent/JP5475279B2/ja active Active
- 2006-06-13 US US11/922,309 patent/US9056090B2/en active Active
- 2006-06-13 WO PCT/EP2006/005697 patent/WO2006133911A2/en active Application Filing
- 2006-06-13 CN CN2006800216989A patent/CN101213204B/zh active Active
- 2006-06-13 EP EP12190520.2A patent/EP2570423B1/en active Active
- 2006-06-13 CA CA2610919A patent/CA2610919C/en active Active
- 2006-06-13 ES ES12190520T patent/ES2948791T3/es active Active
- 2006-06-13 EP EP06743156A patent/EP1893636A2/en not_active Withdrawn
- 2006-06-13 AU AU2006257323A patent/AU2006257323B2/en active Active
-
2008
- 2008-12-31 HK HK08114140.2A patent/HK1123055A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428792B1 (en) * | 1996-05-24 | 2002-08-06 | Chiron Corporation | Hepatitis C virus multiple copy epitope fusion antigens |
WO2003031588A2 (en) * | 2001-10-11 | 2003-04-17 | Merck & Co., Inc. | Hepatitis c virus vaccine |
Also Published As
Publication number | Publication date |
---|---|
HK1123055A1 (en) | 2009-06-05 |
JP5475279B2 (ja) | 2014-04-16 |
CN101213204A (zh) | 2008-07-02 |
EP1893636A2 (en) | 2008-03-05 |
CA2610919A1 (en) | 2006-12-21 |
AU2006257323B2 (en) | 2011-12-22 |
ES2948791T3 (es) | 2023-09-19 |
EP2570423B1 (en) | 2023-05-03 |
AU2006257323A1 (en) | 2006-12-21 |
CA2610919C (en) | 2013-09-10 |
WO2006133911A2 (en) | 2006-12-21 |
US20090035277A1 (en) | 2009-02-05 |
WO2006133911A3 (en) | 2007-04-12 |
JP2008543295A (ja) | 2008-12-04 |
US9056090B2 (en) | 2015-06-16 |
EP2570423A1 (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101213204B (zh) | 丙型肝炎病毒核酸疫苗 | |
US8142794B2 (en) | Hepatitis C virus vaccine | |
CA2583843C (en) | Improved adenoviral vectors and uses thereof | |
AU2002337840A1 (en) | Hepatitis C virus vaccine | |
Vitelli et al. | Chimpanzee adenoviral vectors as vaccines–challenges to move the technology into the fast lane | |
JP2005525085A (ja) | ヒト免疫不全ウイルスに対する遺伝子ワクチン | |
CN101072879A (zh) | 改良的腺病毒载体及其应用 | |
JP2017507672A (ja) | 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法 | |
WO2004097016A1 (en) | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby | |
JP4479973B2 (ja) | C型肝炎ウイルスワクチン | |
Vanniasinkam et al. | Adenoviral gene delivery for HIV-1 vaccination | |
Vogels et al. | High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector | |
CA2718802C (en) | Recombinant nucleic acids comprising regions of ad6 | |
AU2007231692B2 (en) | Hepatitis C virus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1123055 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1123055 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: MSD ITALY S. P. A. Free format text: FORMER OWNER: ANGELETTI P. IST RICHERCHE BIO. Effective date: 20140709 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140709 Address after: Rome Italy Patentee after: MSD Italy S. p. A. Address before: Italy Pomezia Patentee before: Angeletti P. Ist Richerche Bio. |